Afshin Dowlati, MD
Enriched profileDirector, Thoracic Oncology Program, UH Seidman Cancer Center; Lucile and Robert H. Gries Endowed Director, Center for Cancer Drug Development; Professor of Medicine, Case Western Reserve University School of Medicine · University Hospitals Seidman Cancer Center
Afshin Dowlati is Director, Thoracic Oncology Program, UH Seidman Cancer Center; Lucile and Robert H. Gries Endowed Director, Center for Cancer Drug Development; Professor of Medicine, Case Western Reserve University School of Medicine at University Hospitals Seidman Cancer Center. OpenAlex indexes 719 publications with 32,821 citations (h-index 67); ClinicalTrials.gov lists 26 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 25 Aug 2026
Overview
Updated 14 Oct 2026
Afshin Dowlati, MD, is Director, Thoracic Oncology Program, UH Seidman Cancer Center at University Hospitals Seidman Cancer Center / Case Western Reserve University School of Medicine. The public record shows 719 publications with 32,821 citations (h-index 67), centered on Lung Cancer Research Studies, Lung Cancer Treatments and Mutations, Cancer therapeutics and mechanisms. It also documents an investigator role on 26 registered clinical trials, industry payments reported by 25 companies, 6 NIH-funded awards (2004–2026).
- Most recent indexed publication: 2026 · Journal of clinical oncology
- Top research focus: Lung Cancer Research Studies
- 26 registered trials on ClinicalTrials.gov
- Open Payments reporting from 25 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 20 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 247.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 26 registered studies on ClinicalTrials.gov. The most recent:
Industry payments
Updated 14 Oct 2026
25 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- JAZZ PHARMACEUTICALS INC.Program year20259 payments
- AstraZeneca Pharmaceuticals LPProgram year20254 payments
- Amgen Inc.Program year20254 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
43.7%Atypical Antipsychotic21.8%Olanzapine100%Part D≥30 patientsPhenothiazine21.8%Prochlorperazine Maleate100%Part D≥38 patientsMetabolism & gastrointestinal
25.8%Serotonin-3 Receptor Antagonist19.7%Ondansetron Hcl100%Part D≥37 patientsCorticosteroid6.1%Prednisone100%Part D≥11 patientsCancer & immunology
25.3%Kinase inhibitor19.7%Tagrisso67%Alecensa33%Part D<11 patientsOther antineoplastic agents5.7%Lumakras100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
6 NIH research awards on record, funded 2004–2026 per NIH RePORTER. The latest:
Congress activity
Updated 14 Oct 2026
201 congress contributions (2004–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- Abstract CT023: Early clinical activity from the phase 1 evaluation of CID-078, a novel Cyclin A/B-RxL inhibitor, in patients with advanced solid tumors
AACR Annual Meeting
AACR2026Presenting author - Clinical associations of cannabis use among patients receiving immune checkpoint inhibitors: A real-world analysis.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6-Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non-Small Cell Lung Cancer.
Journal of clinical oncology
Clinical Trial2026 - Roles of Restricted Mean Survival Time and Restricted Mean Time Lost in Evaluating Immune Checkpoint Inhibitor Efficacy for Extensive-Stage Small Cell Lung Cancer.
Cancer research communications
Meta-analysis2026 - A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies.
Cancer research communications
Clinical Trial2025 - Comprehensive Analysis of the Value of Dynamic Changes in Circulating Tumor DNA in Small Cell Lung Cancer.
JCO precision oncology
Article2025
Most-cited works
by citation count (OpenAlex)Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/afshin-dowlati-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Afshin-Dowlati-2339816797
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- LinkedIn
linkedin.com/company/dowlatilab
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - X / Twitter
x.com/Latinamd/status/1804144826591346894
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uhhospitals.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uhhospitals.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uhhospitals.org ↗
- Board Certified
Medical Oncology - American Board of Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uhhospitals.org ↗ - Board Certified
Internal Medicine - American Board of Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uhhospitals.org ↗
Editorial & leadership roles
journal and society appointments- Editorial Board member
Journal of Thoracic Oncology (JTO)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →jto.org ↗ - Founding member
NCI Small Cell Lung Cancer Consortium
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →case.edu ↗ - Co-Principal Investigator
NCI Lead Academic Participating Site grant, Case Comprehensive Cancer Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →case.edu ↗
Awards & honors
honors on the public record- Rosalie and Morton A. Cohen Chair in Oncology
UH Seidman Cancer Center (endowed chair)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uhhospitals.org ↗ - Lucile and Robert H. Gries Endowed Director
Center for Cancer Drug Development (endowed directorship)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →case.edu ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →facebook.com ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →case.edu ↗
- Associate Director for Clinical Research
Case Comprehensive Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →case.edu ↗ - Cross-listed faculty
Department of Biochemistry, Case Western Reserve University School of Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →case.edu ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news-medical.net ↗
- IASLC podcast panelist: 'LCC in Farsi' discussion on lung cancer issues in Iran/Middle East
with Hossein Borghaei and Sharareh Seifi
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncodaily.com ↗ - Recurring expert contributor/roundtable panelist
Targeted Oncology (video case-based roundtable on SCLC treatment data)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →targetedonc.com ↗ - Recurring author/contributor
OncLive oncology news and multimedia platform
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Daniel Spratt, MD
University Hospitals Seidman Cancer Center
Theodoros Teknos, MD
University Hospitals Seidman Cancer Center
Joseph Bokar, MD
University Hospitals Seidman Cancer Center
Brett Glotzbecker, MD
University Hospitals Seidman Cancer Center
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Julie Brahmer, MD
Johns Hopkins University School of Medicine
Enriqueta Felip, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center